Koers Amexdrug Corporation Other OTC
Aandelen
AXRX
US0311392072
Farmaceutische producten
Omzet 2011 | 12,41 mln. 11,59 mln. | Omzet 2012 | 9,15 mln. 8,55 mln. | Marktkapitalisatie | 8,46 mln. 7,9 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2011 | - 0 | Nettowinst (verlies) 2012 | - 0 | EV/omzet 2011 | 1,38 x |
Nettoschuld 2011 | 150K 140K | Nettoschuld 2012 | 778K 727K | EV/omzet 2012 | 1,01 x |
K/w-verhouding 2011 |
168
x | K/w-verhouding 2012 |
103
x | Werknemers | - |
Dividendrendement 2011 * |
-
| Dividendrendement 2012 |
-
| Vrij verhandelbaar | 8,4% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Jack Amin
CEO | Chief Executive Officer | 64 | 01-04-00 |
Robert Wilkinson
LAW | General Counsel | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Jack Amin
CEO | Chief Executive Officer | 64 | 01-04-00 |
Behrooz Meimand
BRD | Director/Board Member | 74 | 01-12-01 |
Rodney Barron
BRD | Director/Board Member | 70 | 01-12-01 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+27,42% | 76,68 mld. | |
-0,60% | 24,41 mld. | |
+7,82% | 8,81 mld. | |
+10,46% | 8,48 mld. | |
-25,33% | 7,47 mld. | |
+15,02% | 5,21 mld. | |
+1,24% | 4,12 mld. | |
-8,45% | 3,86 mld. | |
-3,20% | 3,56 mld. |